Albumedix and NYU School of Medicine to investigate targeting novel cellular pathways in oncology
Collaboration will explore the potential of novel applications of Albumedix’s albumin-based drug delivery platform, Veltis.
Albumedix has entered into a collaborative research agreement with the New York University (NYU) School of Medicine. The collaboration will explore the potential of novel applications of Albumedix’s albumin-based drug delivery platform, Veltis, to modulate immune pathways discovered at NYU.
The research collaboration carried out at both the NYU School of Medicine in New York, USA, and at the Albumedix research facility in Nottingham, UK, aims to investigate the potential of Albumedix’s engineered albumin-drug constructs as immuno-oncology therapies using novel immunomodulatory pathways. From NYU, the collaboration will be led by Dr Dafna Bar-Sagi, Vice Dean for Science and Chief Scientific Officer at NYU Langone Medical Center. Dr Bar-Sagi is one of the country’s leading cancer biologists, whose research has had a major impact on the understanding of mechanisms that control tumour initiation and progression. She is widely known for her work on the Ras oncogene and its role in the regulation of cell proliferation and survival, cancer metabolism, and tumour immunity.
Despite significant advancements in treatment options, cancer remains one of the leading causes of morbidity and mortality worldwide. Increasing understanding of the underlying tumour biology in patients is a cornerstone of cancer research and drug development efforts. As part of the collaboration, Dr Bar-Sagi’s laboratory will be responsible for evaluating the immuno-modulatory effect of albumin-drug constructs developed by Albumedix against various pathways involved in the response of immune cells to specific forms of cancer.
“Albumin-based therapies have already offered important benefits to patients worldwide. This collaboration enables us to take another step towards broadening their therapeutic potential,” comments Dr Darrell Sleep, Chief Scientific Officer at Albumedix. “Dr Bar-Sagi and her team are renowned experts who bring an extraordinary understanding of oncology to this collaboration. We are excited to work with them to elucidate the potential therapeutic role of our Veltis technology in oncology.”
Commenting on the collaboration, Dr Bar-Sagi said: “Here at NYU, we have recently identified a number of novel and exciting immunomodulatory pathways in cancer. We look forward to exploring how such pathways can be targeted therapeutically using Albumedix’s technology.“
Albumedix has developed Veltis, a technology platform based on recombinant human albumin variants engineered to improve the therapeutic half-life of APIs connected to Veltis and increase its drug payload capacity. The use of albumin to extend the half-life of therapeutic proteins has been clinically validated through the approvals of GlaxoSmithKline’s (GSK) Tanzeum (GLP-1/albumin fusion for Type 2 Diabetes) and CSL Behring’s Idelvion (rhFactor IX/albumin fusion for Hemophilia). In parallel, Albumedix has been exploring the potential benefits of its Veltis technology in oncology applications. This research collaboration will help expand the mechanistic understanding of how albumin may play a role in facilitating cancer immune regulation.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance